Infectious Diseases Research

Below are current clinical trials.

222 studies in Infectious Diseases Research
(all studies, either open or closed).

Filter this list of studies by location, status and more.

1. Testing of Real-Time Diagnostic Platform (HPView) for the Detection of High-risk HPV Strains in Urine

   Rochester, Minn.

   The purpose of this study is to test whether our developed real-time HPV detection platform (HPView) performs at a comparable level to the clinical gold-standard.

2. A Study of the Quantiferon CMV Blood Test to Predict the Risk of CMV Returning After Treatment of the Disease in Solid Organ Transplant Recipients

   Rochester, Minn.

   The purpose of this study is to determine if a special laboratory test performed on a blood sample collected from you (the organ recipient) can accurately predict the risk CMV infection occurring again in the future, after the current disease is cured.

3. Safety and Efficacy of Investigational Anti-Influenza Immune Plasma in Treating Influenza

   Rochester, Minn.

   This randomized, open-label, multicenter phase 2 trial will assess the safety, efficacy, and pharmacokinetics (PK) of anti-influenza plasma in subjects with influenza A or B. Hospitalized subjects with influenza A or B that have either a low oxygen level or a high respiratory rate will be eligible for study participation. This study will enroll adults, children and pregnant women.

4. A Study to Evaluate Clinical Performance of the Aptima® CMV Quant Assay on the Panther® System

   Rochester, Minn.

   The purpose of this study is to evaluate the clinical performance of the Aptima CMV Quant assay on the Panther system in ethylenediaminetetraacetic acid (EDTA) plasma samples from solid organ transplantation recipients (SOTR) and hematopoietic stem cell transplant recipients (HSCTR).

    

5. A Study of the Donor Screening Experience and the Outcomes from Fecal Transplant in Patients with C. Difficile Infection

   Scottsdale/Phoenix, Ariz., Rochester, Minn.

   The purpose of this study is to evaluate clinical experience with donor screening for fecal transplant, and to evaluate the outcomes from fecal transplant and understand risk factors for fecal transplant failure and relapse after fecal transplant.

6. Laboratory Assay Optimization 2.0

   Rochester, Minn.

   The purpose of this study is to better understand the role of HIV and/or HCV infection and/or SARS-CoV-2 on the immune system and potential ways to eliminate the virus(es).

7. Benznidazole for treatment of Chagas Disease (American trypanosomiasis)

   Scottsdale/Phoenix, Ariz.

   The objective of the treatment program described here is to make benznidazole available in the United States on a compassionate-use basis for treatment of T. cruzi infection—specifically, for patients who have acute or congenital infection, reactivated infection, or chronic infection (without advanced cardiac disease)—and for prophylaxis of infection, when indicated in the setting of proven exposure. Benznidazole will be provided for individual patients who meet the eligibility criteria, on request of the treating physician, after consultation with CDC staff.

8. A Study Using VE303 to Prevent Recurrence of Clostridium Difficile Infection

   Rochester, Minn.

   The purpose of this study will evaluate the safety and effectiveness of VE303 for participants with recurrent Clostridium difficile infection (rCDI).

9. Evaluation of patients perceived health and fitness prior to surgery during the COIVD 19 pandemic

   Rochester, Minn.

   The primary aim of this study is to assess colon and rectal surgery patient perceptions of physical fitness, willingness to participate in a prehabilitation program, access to cardiovascular and strength training equipment, and impact of the COVID19 pandemic on fitness and health. The secondary aim is to evaluate if patient’s perceptions of physical fitness correlate with baseline demographic and health variables and outcomes following surgery.

10. COVID19 Immunology and Omics Study

    Rochester, Minn.

    The purpose of this study is to enumerate dendritic cells, to measure IFN-a production by pDC, and to measure cytokines, growth factors, proteins and metabolites/lipids, and to develop a predictive laboratory score for stratifying COVID-19+ individuals into subgroups with different prognoses and therapeutic needs. 

    Plasmacytoid dendritic cells (pDCs) specialize in producing type I interferons (IFN-I). As such, they play an important role as an early line of defense against viral infections.

    The majority of COVID-19+ individuals follow an uncomplicated course, with a smaller subset of patients requiring hospitalization or intensive care level support.

    Early pDC enumeration in the peripheral blood and assessment of IFN-a could help predict outcomes of COVID-19+ individuals.

    Additional assessment of cytokines, growth factors, proteins (including complement proteins, clotting factors, adhesion molecules, matrix proteins, receptors, lectins, and tissue injury factors) and metabolites/lipids in COVID-19+ individuals would enable an accurate understanding of the pathophysiology of different complications observed in patients infected with SARS-CoV-2 during the inflammatory state of the disease (e.g. myocarditis, acute renal disease, thrombosis).